| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
113,340,000 |
| Market
Cap: |
108.83(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6758 - $2.34 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
41,140 |
41,140 |
| Total Buy Value |
$0 |
$0 |
$49,985 |
$49,985 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
924,350 |
1,173,939 |
1,216,699 |
1,560,865 |
| Total Sell Value |
$901,474 |
$1,198,663 |
$1,255,793 |
$3,019,031 |
| Total People Sold |
4 |
7 |
7 |
8 |
| Total Sell Transactions |
8 |
26 |
36 |
61 |
| End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
147,000 |
298,401 |
|
- |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
188,205 |
351,977 |
|
- |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
198,959 |
420,458 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
442,800 |
1,264,253 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2024-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
188,205 |
432,605 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2024-02-27 |
4 |
S |
$1.32 |
$3,369 |
D/D |
(2,545) |
244,400 |
|
31% |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2024-02-15 |
4 |
S |
$1.33 |
$7,783 |
D/D |
(5,847) |
163,772 |
|
25% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2024-02-06 |
4 |
S |
$1.59 |
$6,671 |
D/D |
(4,205) |
246,945 |
|
41% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2024-02-06 |
4 |
S |
$1.59 |
$6,365 |
D/D |
(4,012) |
821,453 |
|
41% |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
13,333 |
169,619 |
|
- |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
14,167 |
221,499 |
|
- |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,167 |
151,401 |
|
- |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
14,167 |
172,397 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
13,333 |
251,150 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2024-01-24 |
4 |
A |
$0.00 |
$0 |
D/D |
42,000 |
825,465 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2024-01-04 |
4 |
S |
$0.82 |
$3,373 |
D/D |
(4,114) |
783,465 |
|
-37% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-12-04 |
4 |
S |
$0.79 |
$2,861 |
D/D |
(3,622) |
787,579 |
|
-32% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-11-06 |
4 |
S |
$0.92 |
$3,319 |
D/D |
(3,606) |
791,201 |
|
-67% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-10-04 |
4 |
S |
$1.27 |
$4,558 |
D/D |
(3,589) |
794,807 |
|
-3% |
|
| Bohlin Garen G |
|
– • – |
2023-09-12 |
4 |
B |
$1.22 |
$49,985 |
D/D |
41,140 |
45,140 |
0.01 |
-36% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-09-05 |
4 |
S |
$1.32 |
$4,817 |
D/D |
(3,622) |
798,396 |
|
41% |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2023-09-01 |
4 |
S |
$1.33 |
$9,872 |
D/D |
(7,415) |
204,086 |
|
46% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2023-09-01 |
4 |
S |
$1.33 |
$9,203 |
D/D |
(6,913) |
237,817 |
|
46% |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2023-09-01 |
4 |
S |
$1.33 |
$5,176 |
D/D |
(3,888) |
142,234 |
|
46% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2023-08-07 |
4 |
S |
$1.72 |
$6,402 |
D/D |
(3,722) |
802,018 |
|
52% |
|
620 Records found
|
|
Page 2 of 25 |
|
|
0.01 (1.31%) 
